TPUSA was founded in 1998 to accelerate Takeda's global expansion into the U.S. market. The acquisition will contribute significantly to Takeda's revenues, operating income, and … Addition of Colcrys® (colchicine) to Takeda's Gout Treatment Portfolio Will Immediately Contribute to Company's Revenue. DEERFIELD -- Takeda Pharmaceutical Co. subsidiary Takeda America Holdings, Inc. has acquired URL Pharma Inc. for $800 million. NSE: SUNPHARMA, BSE: 524715) announced today that Caraco Pharmaceutical Laboratories, Ltd. (Caraco), its wholly-owned subsidiary, has entered into a definitive agreement with Takeda Pharmaceuticals U.S.A., Inc, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, to buy the URL Pharma, Inc.* generic business. It is not certain that Uloric caused these events. Net sales for Colcrys in calendar year 2011 were more than $430 million, and continued growth of Colcrys sales is expected through the product's lifecycle. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda has chosen to continue the Patient Assistance Program (PAP) extended to the Chinese Shar-Pei owners for Colcrys® (colchicine). If you are looking for specific information,please visit our country/region website. 3 Speen Street, Suite 300, Framingham, MA 01701. Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease, Improving Access to Healthcare in Remote Communities, FY2020 Q3 Results (February 4, 2021)Webcast / Audio Conference Call (for Investors, Analysts and Media) 8:00pm-9:00pm JST (Presentation and Q&A Session), Information for US Patients Regarding the NATPARA Recall in the US. To learn more about Takeda, visit www.tpna.com . URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc., and report to Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. Applicants must provide a valid Colcrys® prescription from a … Innovation in Rare Disease: Making Progress with Cell & Gene Therapies – A Webinar Series from the Rare Disease Innovations Institute and Syneos Health®. Upon completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc. See: Sun Pharmaceutical Industries Inc. The new complaint echoes one Par faced from Mutual Pharmaceutical Co. in April 2012, about the time Takeda acquired Mutual parent URL Pharma … Japan-based drug manufacturer Takeda Pharmaceutical is to acquire the US pharmaceutical firm URL Pharma for an upfront payment of $800m. The new application form is on my web site Home Page www.drjwv.com) and should be used from now on. Upon completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals … It is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company and one with a … If you believe you have been contacted by an unauthorized person, please contact your local law enforcement agency immediately. Contacts:Takeda Pharmaceuticals U.S.A., Inc.Elissa J. Takeda has chosen to continue the Patient Assistance Program (PAP) extended to the Chinese Shar-Pei owners for Colcrys® (colchicine). exclude terms. Individual results may vary. The deal is the latest in a number of transactions by Japanese companies looking to expand their presence overseas. The new application form is on my web site Home Page and should be used from now on. 19, 2011 at 2:16 a.m. The respective companies currently market oral diabetes, insomnia, rheumatology, gastroenterology, and cardiovascular … DEERFIELD, Ill. — Takeda Pharmaceutical Co. plans to buy URL Pharma Inc. for $800 million. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; the transaction may not be consummated; the anticipated benefits of the transaction may not be realized; the transaction could disrupt relationships with employees, licensees, customers and other business partners or governmental entities; future sales of Colcrys could be adversely affected by competition or other factors; and integration costs may exceed current expectations. Takeda Pharmaceutical has announced new, late-breaking Phase III data from the TAK-620-303 (SOLSTICE)… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Tell your healthcare provider about all your medical conditions and all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Takeda has chosen to continue the Patient Assistance Program (PAP) extended to the Chinese Shar-Pei owners for Colcrys® (colchicine). More Clinical Trial Websites This site was created to provide patients, their family members, health care professionals, researchers and the general public with information about Takeda-sponsored clinical trials. The deal also may include future performance-based payments. Takeda is an R&D driven, global biopharmaceutical leader. Takeda’s recruiting correspondence will be sent by a recruiting representative with an @takeda.com email address – not @gmail.com, @yahoo.com, @hotmail.com or any other email domain service. (for Investors, Analysts and Media) 8:00pm-9:00pm JST (Presentation and Q&A Session). Addition of Colcrys® (colchicine) to Takeda's Gout Treatment Portfolio Will Immediately Contribute to Company's Revenue URL Pharma, Inc. (Dungan Road) 7722 Dungan Road. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made. Takeda Pharmaceutical Co is selling its USA-based URL Pharma generic business, ie excluding the gout drug Colcrys, to Sun Pharmaceutical Industries' Caraco unit. Share Article The gout treatment manufacturer has achieved relative success with its lead product Colcrys, used to treat flare-ups of gout, which recorded revenue in excess of $430m in 2011. Applicants must provide a valid … Its leading product is Colcrys (colchicine) - … Takeda has chosen to continue the Patient Assistance Program (PAP) extended to the Chinese Shar-Pei owners for Colcrys® (colchicine). Acquisition amount: $800 million - The deal includes agreements stipulating Takeda will make future performance-based contingent earn out payments to URL Pharma's current owners beginning in 2015. Use a + to require a term in results and - to URL Pharma was recently purchased by Takeda Pharaceuticals, USA. URL Pharma was recently purchased by Takeda Pharmaceuticals, USA (2012). The projected impact of this acquisition on Takeda's consolidated financial statements will be reflected in Takeda's fiscal 2012 outlook and Mid-Range Plan 2012-14, the outline of which will be announced on May 11, 2012. Takeda to Acquire URL Pharma - Takeda to Acquire URL Pharma Relationship with Takeda: No matters to report regarding capital, personal and transactional relationship between Takeda and URL Pharma. We are pleased to have URL Pharma's Colcrys added to our product portfolio and look forward to further realizing our goal of helping patients by providing multiple treatment options to manage the symptoms of acute and chronic gout in the U.S.". On 25 May 2012, Takeda purchased Brazilian pharmaceutical company Multilab for R$540 million. Subscribe to FiercePharma to get industry news and updates delivered to your inbox. On June 4, 2012, Takeda Pharmaceuticals U.S.A., Inc., completed its acquisition of URL Pharma, Inc. Takeda Pharmaceuticals U.S.A., Inc. is a subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The gout treatment manufacturer has achieved relative success with its lead product Colcrys, used to treat flare-ups of gout, which recorded revenue in excess of $430m in 2011. The acquisition will contribute significantly to Takeda's revenues, operating income, and free cash flow beginning in fiscal year (FY) 2013. The acquisition will contribute significantly to Takeda’s revenues, operating income, and free cash flow from 2013, the firm said. The addition of Colcrys strengthens Takeda… 26-11-2020. DEERFIELD, Ill., OSAKA, Japan, and PHILADELPHIA, April 11, 2012-- Takeda Pharmaceutical Company Limited (Takeda) and URL Pharma Inc. (URL Pharma) jointly announced today that Takeda's wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma - a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments. The new application form is on my web site Home Page (www.drjwv.com) and should be used from now on. Copyright 1995-2021 Takeda Pharmaceutical Company Limited. Based in Deerfield, Ill., Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, and is among the top 15 pharmaceutical companies in the United States. Deerfield, IL 60015. Celebrating the grand opening of Takeda Global Headquarters, Harnessing the power of people to transform health care, Progress, Promise and a Path Forward: A Look Inside Takeda’s Wave 1 Pipeline, Using a Global Network of Adaptive Clinical Trials to Fight COVID-19, Global Ethics & Compliance / Global Code of Conduct, We will become a global, values-based, R&D-driven, biopharmaceutical leader, Supplier Registration Process via Ariba Commerce Cloud, A selection of stories related to Innovation, Caring and Heritage, Takeda Leaders Highlight Continued Business Transformation at Virtual J.P. Morgan Healthcare Conference, The Key Elements at the Heart of Our Innovation, New In Their Shoes Experience Simulates Short Bowel Syndrome with Intestinal Failure, Shifting paradigms of COVID-19 reflections from the 75th UN General Assembly, Harnessing the Power of People to Transform Health Care, Shared Knowledge for a Better Life for All. 28-11-2020. Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) is committed to strive toward better health for patients through leading innovation in medicine. After a long history of generic pharmaceutical research, development, and manufacturing, the Company has successfully transitioned to a technology-driven, specialty pharmaceutical business. Other economic provisions are not disclosed. * Takeda to pay $800 mln cash plus performance-based payments * Takeda to pay $800 mln cash plus performance-based payments ... UPDATE 1-Japan's Takeda to buy URL Pharma for $800 … The most common side effects of Uloric are liver problems, nausea, gout flares, joint pain, and rash. The company currently markets oral diabetes, insomnia, rheumatology, gastroenterology and cardiovascular treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, gastroenterology, neurology and other conditions. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. URL, which specialises in treatments for gout, will also be eligible for future performance-based payments. The acquisition will result in an immediate increase in revenue with estimated FY 2012 net sales of more than $550 million, and continued growth of Colcrys sales is expected throughout the product’s lifecycle. Takeda is committed to addressing the world’s biggest challenges to sustainable development over the long term. Or, if … Tell your healthcare professional about liver or kidney problems or a history of heart disease or stroke. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements. Brazil's antitrust regulator CADE said on Wednesday it had cleared the way for Hypera Pharma to buy a portfolio of productions from Japan's Takeda Pharmaceutical Co. URL Pharma had revenues of nearly $600m in 2011. You have a higher chance for muscle problems if you are elderly, taking certain other medicines with Colcrys or have impaired kidney function. Takeda Pharma to buy Nycomed for $13.6 bln May. "This acquisition expands Takeda's gout treatment portfolio and leverages our expertise in primary care," said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. "Gout affects more than eight million Americans, and the prevalence of gout is rising. Takeda is an R&D driven, global biopharmaceutical leader. URL is headquartered in Philadelphia, and its lead product is Colcrys, which is used to treat gout flare-ups. In June 2012, Takeda announced it would acquire URL Pharma, then run by the founder's son Richard Roberts, for US$800 million. A small number of heart attacks, strokes, and heart-related deaths were seen in clinical studies. Your healthcare professional may do blood tests to check your liver function while you are taking Uloric. Fit within Takeda's existing infrastructure. URL Pharma will be managed by Takeda Pharmaceuticals USA, Inc., and report to Douglas Cole, president, Takeda Pharmaceuticals USA, Inc. Upon completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc. Colcrys is not a pain medicine and it should not be taken to treat pain related to other conditions unless specifically prescribed for those conditions. For more information, refer to the patient Medication Guide. URL Pharma was recently purchased by Takeda Pharmaceuticals, USA (2012). Japan-based drug manufacturer Takeda Pharmaceutical is to acquire the US pharmaceutical firm URL Pharma for an upfront payment of $800m. Takeda only bought URL in June, in an $800 million deal that was principally driven by the desire to get access to Colcrys (colchicine). For over 200 years, we’ve focused on bringing better health and a brighter future to people around the world by translating science into life-changing medicines that make a critical difference for patients. Japanese drugmaker Takeda Pharmaceutical Co. Ltd. said Wednesday it will pay $800 million upfront to buy the privately held U.S. gout treatment maker URL Pharma Inc. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient Engagement, Stocks: NYSE:TAK,TSE:4502, release date:Feb 18, 2021 URL Pharma, Inc., headquartered in Philadelphia, PA, is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient Engagement, Stocks: NYSE:TAK,TSE:4502, release date:Feb 18, 2021 Takeda Pharmaceutical Company, via its subsidiary Takeda America Holdings, is acquiring URL Pharma, a Philadelphia-based privately held pharma company. Its leading product is Colcrys (colchicine) for the treatment and … The Takeda Pharmaceutical Company of Japan agreed on Wednesday to buy URL Pharma for $800 million, plus potential further payments based on the company’s performance. Takeda To Acquire URL Pharma Takeda Pharmaceutical Co. has entered an agreement to acquire URL Pharma, a privately held pharmaceutical company based in Philadelphia, PA, for an upfront payment of $800 million and future performance-based milestones. URL Pharma is a pharmaceutical company with 2011 calendar year revenues of nearly $600 million. Upon closing, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc. [ILLUSTRATION OMITTED] URL Pharma … The acquisition will contribute significantly to Takeda’s revenues, operating income, and free cash flow from 2013, the firm said. You are encouraged to report negative side effects of prescription drugs to the FDA. Pending the satisfaction of customary closing conditions, the deal is expected to close within 60 days. For additional information about the company, please visit www.urlpharma.com . Upon completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc. Takeda Pharmaceuticals U.S.A., Inc. One Takeda Parkway. Takeda Pharma to buy Nycomed for $13.6 bln May. Upon completion of the acquisition, URL Pharma will be managed by Deerfield, Ill.-based Takeda Pharmaceuticals Takeda Pharmaceutical has announced new, late-breaking Phase III data from the TAK-620-303 (SOLSTICE)… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. This information is not intended to replace discussions with a healthcare provider. Takeda Pharmaceutical has agreed a deal to purchase US-based URL Pharma for an upfront payment of $800m. Sun Pharma acquired the URL Pharma generic business from Takeda in December 2012. Takeda expects the acquisition of URL Pharma will: Enhance Takeda's gout treatment portfolio and allow it to provide multiple treatment options to patients and healthcare providers to manage acute and chronic gout in the U.S. URL Pharma, Inc. URL Pharma, Inc. was acquired by Takeda Pharmaceutical Company in June 2012. Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements, Stocks: NYSE:TAK, release date:Feb 03, 2021 This press release contains "forward-looking statements. Takeda Pharma Vertrieb GmbH und Co. KG is Takeda´s German center for Marketing and Sales of our products. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. 19, 2011 at 2:16 a.m. URL Pharma will be managed by Takeda Pharmaceuticals USA, Inc., and report to Douglas Cole, president, Takeda Pharmaceuticals USA, Inc. News provided by. Singapore: Takeda Pharmaceutical Company acquired URL Pharma through its wholly-owned subsidiary Takeda America Holdings (TAH), for an upfront payment of $800 million in cash and future performance-based contingent earn out payments. Takeda to acquire URL Pharma for $800 million 12-04-2012 Print. ET by Lisa Twaronite Takeda expected to buy Nycomed for $12.3B: report For over 200 years, we’ve focused on bringing better health and a brighter future to people around the world by translating science into life-changing medicines that make a critical difference for patients. "Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth of Colcrys or any assumptions underlying any of the foregoing. Additional Paid-in Capital: $1,870,000 - Main shareholders are two venture capital investors, Elliott Associates L.P. and Momar Corporation, and Dr. Richard H. Roberts. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. URL Pharma, Inc. (Orthodox St) 1100 Orthodox Street Philadelphia, PA 19124. The Takeda Pharmaceutical Company of Japan agreed on Wednesday to buy URL Pharma for $800 million, plus potential further payments based on the company’s performance. Pending the satisfaction of customary closing conditions, the deal is expected to close within 60 days. ET by Lisa Twaronite Takeda expected to buy Nycomed for $12.3B: report Colcrys complements Takeda's position in the gout marketplace with Uloric (febuxostat), used to lower blood uric acid levels in adults with gout. URL Pharma is a pharmaceutical … The addition of Colcrys strengthens Takeda… Additional information about Takeda is available through its corporate website, www.takeda.com . Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber speaks during a press conference on January 7, 2019 in Tokyo, Japan. Upon completion of the transaction, URL Pharma will be managed by Takeda Pharmaceuticals USA. In June 2012, Takeda announced it would acquire URL Pharma, then run by the founder's son Richard Roberts, for US$800 million. The acquisition of URL Pharma strengthens Takeda’s offerings in the U.S. pharmaceutical market by providing patients with more gout management options to treat and prevent gout flares and the high uric acid levels associated with the condition. Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. DEERFIELD -- Takeda Pharmaceutical Co. subsidiary Takeda America Holdings, Inc. has acquired URL Pharma Inc. for $800 million. Certified as a Global Top Employer, we offer stimulating careers, encourage innovation, and strive for excellence in everything we do. Takeda Completes Acquisition of URL Pharma, Inc. Applicants must provide a valid Colcrys® prescription from a licensed veterinarian and must … Join patients and their families, legislators, industry experts, advocates and sponsors to discuss education initiatives, recent advancements and the future promise of cell and gene medicine, and current patient experiences with these therapies. Pending the satisfaction of customary closing conditions, the deal is expected to close within 60 days. At Takeda, we are transforming the pharmaceutical industry through our R&D - driven market leadership and being a values-led company. URL Pharma will be managed by Takeda Pharmaceuticals USA, Inc., and report to Douglas Cole, president, Takeda Pharmaceuticals USA, Inc. The most common side effects in people who have gout flares are diarrhea and throat pain. +81-3-3278-2037, © 2021 Questex LLC. The acquisition of URL Pharma strengthens Takeda’s offerings in the U.S. pharmaceutical market by providing patients with more gout management options to treat and prevent gout flares and the high uric acid levels associated with the condition. Takeda is a research-based global company with its main focus on pharmaceuticals. Following the acquisition, Takeda Pharmaceuticals, US, will now manage URL Pharma, whose major shareholders include Elliott … Statements made in the future tense, and words such as "anticipate," "expect," "project," "continue," "believe," "plan," "estimate," "pro forma," "intend," "potential," "target," "forecast," "guidance," "outlook," "seek," "assume," "will," "may," "should," and similar expressions are intended to qualify as forward-looking statements. Its leading product is Colcrys (colchicine) - used to treat and prevent gout flares. Visit www.fda.gov/medwatch , or call 1-800-FDA-1088. The acquisition will result in an immediate increase in revenue with estimated FY 2012 net sales of more than $550 million, and continued growth of Colcrys sales is expected throughout the product’s lifecycle. All rights reserved. Takeda Pharmaceutical Co is selling its USA-based URL Pharma generic business, ie excluding the gout drug Colcrys, to Sun Pharmaceutical Industries' Caraco unit. In addition, the combined business could be adversely affected by industry, economic or political conditions outside of URL Pharma's or Takeda's control, including general economic conditions in Japan, the United States and worldwide; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development. Article Takeda takes vaccine investment at German site beyond 200 million euros. Takeda's shareholders approved the … It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients … URL Pharma was recently purchased by Takeda Pharaceuticals, USA. Uloric is a prescription medicine used to lower blood uric acid levels in adults with gout. Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma – a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments. Upon completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc. Takeda To Acquire URL Pharma Takeda Pharmaceutical Co. has entered an agreement to acquire URL Pharma, a privately held pharmaceutical company based in Philadelphia, PA, for an upfront payment of $800 million and future performance-based milestones. Enclose phrases in quotes. The new application form is on my web site Home Page and should be used from now on. Article Japan nod for HCC indication on Takeda’s Cabometyx. On 25 May 2012, Takeda purchased Brazilian pharmaceutical company Multilab for R$540 million. [email protected], Takeda Pharmaceutical Company LimitedCorporate Communications Dept. Financial advisor to Takeda: Goldman, Sachs & Co. Legal advisor to Takeda: Sidley Austin, LLP, Financial advisor to URL Pharma: J.P. Morgan Securities LLC, Legal advisor to URL Pharma: Ropes & Gray LLP, Location of executive offices: Philadelphia, Pennsylvania, Representative: Richard H. Roberts, M.D., Ph.D., President, CEO and Chairman. Keep Colcrys out of the reach of children. The acquisition will result in an immediate increase in revenue with estimated FY 2012 net sales of more than $550 million , and continued growth of Colcrys sales is expected throughout the product's lifecycle. You are encouraged to report negative side effects of prescription drugs to the FDA.Visit www.fda.gov/medwatch or call 1-800-FDA-1088.You may also report negative side effects to the manufacturer of Colcrys by calling1.888.351.3786. URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc., and report to Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. "URL Pharma is pleased to become a part of a leading research-based global pharmaceutical company," said Richard H. Roberts, M.D., Ph.D., Chief Executive Officer, and Chairman of the Board, URL Pharma. Learn more about Takeda’s efforts to produce plasma-derived therapies. URL, which specialises in treatments for gout, … To do this, we empower our people to realize their potential through life-changing work. On 26 September 2014, Takeda announced it would team up with BioMotiv to identify and develop … Colcrys can cause serious side effects or death if levels of Colcrys are too high in your body. Your healthcare provider may give you other medicines to help prevent your gout flares. Other stories of interest. URL Pharma had revenues of … Uloric is not for the treatment of high uric acid without a history of gout. All marketing campaigns for the German market are developed, executed and controlled in Berlin. Source: GlobalData, Pharma Intelligence Center, [Accessed 19 th Dec 2017] Figure 1 displays the sales values of the top ten products of Takeda for 2016. Takeda Pharmaceutical has agreed a deal to purchase US-based URL Pharma for an upfront payment of $800m. Colcrys (colchicine, USP) is a prescription medicine used in adults to prevent gout flares and treat gout flares when taken at the first sign of a flare. Contribute to revenues and non-GAAP operating income immediately, with estimated 2012 net sales of more than $550 million and expected continued growth of Colcrys sales through the product's lifecycle. Most Read. URL Pharma is a pharmaceutical company with 2011 calendar year revenues of nearly $600 million. Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. Upon completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc. The Company seeks to develop and commercialize scientifically and medically innovative products that address unmet medical needs for improvements in safety and efficacy. Upon closing, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc. Takeda Pharmaceutical Company Limited (Takeda), a research-based global company, and Philadelphia, Pennsylvania-based privately-held pharmaceutical company, URL Pharma Inc. jointly announced that Takeda’s wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma for an … The companies said Wednesday that the deal, which also includes future performance-based payments to Takeda, is expected to close within the next couple of months. Your gout may flare up when you start taking Uloric; do not stop taking your Uloric even if you have a flare. Takeda Completes Acquisition of URL Pharma, Inc. Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested Colcrys. The drug, … We foster an … The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical and biopharmaceutical company. URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc., and report to Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. Acquiring company: Takeda America Holdings, Inc. Shareholders of URL Pharma: Elliott Associates L.P., Momar Corporation and Dr. Richard H. Roberts, Number of common and preferred stock equivalent to common outstanding shares: 356,669.